AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

A new biotech flashpoint: human growth hormone. (drug manufactured by Genentech Inc.)

San Francisco Business Times

| March 25, 1994 | Davey, Tom | COPYRIGHT 1987 San Francisco Business Times, Inc. (Hide copyright information)Copyright

The public advocacy group that instigated a national controversy over genetically engineered bovine growth hormone is now setting its sights on a drug manufactured by Genentech Inc.

The Washington, D.C.-based Foundation on Economic Trends is charging that Genentech-made human growth hormone, a drug used to treat growth disorders in children, is being widely abused and should come under the stringent regulation of the federal Drug Enforcement Administration.

The foundation claims human growth hormone, marketed by Genentech under the name Protropin and Nutropin, is being prescribed by doctors for questionable purposes not approved by the U.S. Food and Drug Administration, such as to help bodybuilders increase muscle mass. Within the next two weeks, the organization plans to file a petition with the DEA in an effort to have the drug placed in the same restrictive category as anabolic steroids.

South San Francisco-based Genentech generated $217 million last year from Protropin and Nutropin sales.

The FDA has approved use of …

Related articles from newspapers, magazines, journals, and more
Prolor Biotech awarded Israeli Government grant of up to $1.6 M for its...
News wire article from: Chemical Business Newsbase April 12, 2010 700+ words
Prolor Biotech reports positive top-line results from Phase I study of its...
News wire article from: Chemical Business Newsbase February 2, 2010 700+ words
Growth hormone limited in value for rejuvenation. (human growth hormone)
Newspaper article from: NCAHF Newsletter May 1, 1996 700+ words
Paying to turn back time on the aging process.(use of human growth hormone...
Magazine article from: San Francisco Business Times RHINE, JON January 21, 2000 700+ words
Generex Biotechnology initiates feasibility study with Acertus for oral...
News wire article from: Asia Africa Intelligence Wire December 11, 2003 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily